Bevacizumab Biosimilar Efficacy, Safety for Patients With Metastatic Colorectal Cancer
According to a real-world study, the biosimilar bevacizumab-awwb was found to be as effective and safe as the bevacizumab reference product for the treatment of patients with metastatic colorectal cancer.
An observational, longitudinal, cohort study included 1445 patients with metastatic colorectal cancer from 4 integrated care delivery systems in the United States. All patients were newly initiated on the bevacizumab biosimilar (n = 239, between July 1, 2019, and March 30, 2020) or the bevacizumab reference product (n = 1206, between July 1, 2015, and June 30, 2018). Following treatment initiation, patients were followed for either 1 year, until end of plan membership, or death.
The primary outcome of overall survival was analyzed for non-inferiority, with secondary outcomes including counts of doses received, treatment duration, all-cause hospitalizations, and incidence of serious adverse events.
The overall survival rate of patients receiving the biosimilar was 72.8%, compared to 73.1% of patients receiving the bevacizumab reference product (P < .01 for non-inferiority). The adjusted hazard ratio for all-cause mortality was 1.01 (0.77 to 1.33; P = .93). There were no differences in secondary outcomes between the 2 groups.
The study authors concluded, “These findings suggest that bevacizumab-awwb is as effective and safe as bevacizumab reference product for the real-world treatment of [metastatic colorectal cancer].”
Source:
Pham C, Delate T, Buchschacher GL Jr, et al. Real-world clinical outcomes of bevacizumab-awwb biosimilar versus bevacizumab reference product in patients with metastatic colorectal cancer. BioDrugs. Published online September 25, 2023. doi:10.1007/s40259-023-00624-3
